Literature DB >> 7560098

Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus.

H Tsukaguchi1, H Matsubara, S Taketani, Y Mori, T Seido, M Inada.   

Abstract

Nephrogenic diabetes insipidus (NDI) is most often an X-linked disorder in which urine is not concentrated due to renal resistance to arginine vasopressin. We recently identified four vasopressin type 2 receptor gene mutations in unrelated X-linked NDI families, including R143P, delta V278, R202C, and 804insG. All these mutations reduced ligand binding activity to < 10% of the normal without affecting mRNA accumulation. To elucidate whether the receptors are expressed on the cell surface, we analyzed biosynthesis and localization of tagged or untagged receptors stably expressed in Chinese hamster ovary (CHO) cells, using two antibodies directed against distinct termini. Whole-cell and surface labeling studies revealed that the R202C clone had both surface-localized (50-55 kD) and intracellular proteins (40 and 75 kD), similar to the wild-type AVPR2 clone, whereas the R143P and delta V278 clones lacked the surface receptors, despite relatively increased intracellular components. The 804insG mutant cell produced no proteins despite an adequate mRNA level. Immunofluorescence staining confirmed that the R202C mutant reaches the cell surface, whereas the R143P and delta V278 mutants are retained within the cytoplasmic compartment. Thus, R202C, R143P/delta V278, and 804insG result in three distinct phenotypes, that is, a simple binding impairment at the cell surface, blocked intracellular transport, and ineffective biosynthesis or/and accelerated degradation of the receptor, respectively, and therefore are responsible for NDI. This phenotypic classification will help understanding of molecular pathophysiology of this disorder.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7560098      PMCID: PMC185843          DOI: 10.1172/JCI118252

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Epinephrine and dDAVP administration in patients with congenital nephrogenic diabetes insipidus. Evidence for a pre-cyclic AMP V2 receptor defective mechanism.

Authors:  D G Bichet; M Razi; M F Arthus; M Lonergan; P Tittley; R K Smiley; G Rock; D J Hirsch
Journal:  Kidney Int       Date:  1989-11       Impact factor: 10.612

2.  The effect of eight V2 vasopressin receptor mutations on stimulation of adenylyl cyclase and binding to vasopressin.

Authors:  Y Pan; P Wilson; J Gitschier
Journal:  J Biol Chem       Date:  1994-12-16       Impact factor: 5.157

3.  Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus.

Authors:  D G Bichet; M Razi; M Lonergan; M F Arthus; V Papukna; C Kortas; J N Barjon
Journal:  N Engl J Med       Date:  1988-04-07       Impact factor: 91.245

4.  Mutations in the vasopressin V2-receptor gene in three families of Italian descent with nephrogenic diabetes insipidus.

Authors:  V Faà; M L Ventruto; S Loche; M Bozzola; R Podda; A Cao; M C Rosatelli
Journal:  Hum Mol Genet       Date:  1994-09       Impact factor: 6.150

5.  Novel mutations in the V2 vasopressin receptor gene of patients with X-linked nephrogenic diabetes insipidus.

Authors:  D Wenkert; J J Merendino; A Shenker; N Thambi; G L Robertson; A M Moses; A M Spiegel
Journal:  Hum Mol Genet       Date:  1994-08       Impact factor: 6.150

6.  The structure of an antigenic determinant in a protein.

Authors:  I A Wilson; H L Niman; R A Houghten; A R Cherenson; M L Connolly; R A Lerner
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

7.  Changes of atrial natriuretic peptide and its messenger RNA with development and regression of cardiac hypertrophy in renovascular hypertensive rats.

Authors:  H Matsubara; J Yamamoto; Y Hirata; Y Mori; S Oikawa; M Inada
Journal:  Circ Res       Date:  1990-01       Impact factor: 17.367

8.  Two vasopressin type 2 receptor gene mutations R143P and delta V278 in patients with nephrogenic diabetes insipidus impair ligand binding of the receptor.

Authors:  H Tsukaguchi; H Matsubara; Y Mori; Y Yoshimasa; T Yoshimasa; K Nakao; M Inada
Journal:  Biochem Biophys Res Commun       Date:  1995-06-26       Impact factor: 3.575

9.  An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system.

Authors:  M Birnbaumer; S Gilbert; W Rosenthal
Journal:  Mol Endocrinol       Date:  1994-07

10.  Expression studies of two vasopressin V2 receptor gene mutations, R202C and 804insG, in nephrogenic diabetes insipidus.

Authors:  H Tsukaguchi; H Matsubara; M Inada
Journal:  Kidney Int       Date:  1995-08       Impact factor: 10.612

View more
  15 in total

1.  The nuclear translocation assay for intracellular protein-protein interactions and its application to the Bcr coiled-coil domain.

Authors:  Andrew S Dixon; Carol S Lim
Journal:  Biotechniques       Date:  2010-07       Impact factor: 1.993

Review 2.  Controlling protein compartmentalization to overcome disease.

Authors:  James R Davis; Mudit Kakar; Carol S Lim
Journal:  Pharm Res       Date:  2006-09-13       Impact factor: 4.200

Review 3.  Congenital nephrogenic diabetes insipidus: the current state of affairs.

Authors:  Daniel Wesche; Peter M T Deen; Nine V A M Knoers
Journal:  Pediatr Nephrol       Date:  2012-03-17       Impact factor: 3.714

4.  Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.

Authors:  J P Morello; A Salahpour; A Laperrière; V Bernier; M F Arthus; M Lonergan; U Petäjä-Repo; S Angers; D Morin; D G Bichet; M Bouvier
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

5.  Analysis of a novel AVPR2 mutation in a family with nephrogenic diabetes insipidus.

Authors:  Sung-Dae Moon; Ju-Hee Kim; Joo-Yun Shim; Dong-Jun Lim; Bong-Yun Cha; Je-Ho Han
Journal:  Int J Clin Exp Med       Date:  2010-11-30

6.  Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3.

Authors:  Raphael Rozenfeld; Lakshmi A Devi
Journal:  FASEB J       Date:  2008-02-11       Impact factor: 5.191

7.  Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus.

Authors:  Frédéric Jean-Alphonse; Sanja Perkovska; Marie-Céline Frantz; Thierry Durroux; Catherine Méjean; Denis Morin; Stéphanie Loison; Dominique Bonnet; Marcel Hibert; Bernard Mouillac; Christiane Mendre
Journal:  J Am Soc Nephrol       Date:  2009-09-03       Impact factor: 10.121

8.  X-Linked Recessive form of Nephrogenic Diabetes Insipidus in a 7-Year-Old Boy.

Authors:  A Janchevska; V Tasic; Z Gucev; M Krstevska-Konstantinova; H I Cheong
Journal:  Balkan J Med Genet       Date:  2015-04-10       Impact factor: 0.519

9.  Cell surface delivery and structural re-organization by pharmacological chaperones of an oligomerization-defective alpha(1b)-adrenoceptor mutant demonstrates membrane targeting of GPCR oligomers.

Authors:  Meritxell Canals; Juan F Lopez-Gimenez; Graeme Milligan
Journal:  Biochem J       Date:  2009-01-01       Impact factor: 3.857

Review 10.  Inside job: ligand-receptor pharmacology beneath the plasma membrane.

Authors:  Joseph J Babcock; Min Li
Journal:  Acta Pharmacol Sin       Date:  2013-05-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.